巨细胞动脉炎

Ponte C, Grayson PC, Robson JC, et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Arthritis Rheumatol. 2022 Dec;74(12):1881-9. 摘要

Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021 Aug;73(8):1349-65.全文  摘要

Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018 May;77(5):636-43.全文  摘要

1. Ponte C, Grayson PC, Robson JC, et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Arthritis Rheumatol. 2022 Dec;74(12):1881-9. 摘要

2. Dinkin M, Johnson E. One giant step for giant cell arteritis: updates in diagnosis and treatment. Curr Treat Options Neurol. 2021;23(2):6.全文  摘要

3. Caselli RJ, Daube JR, Hunder GG, et al. Peripheral neuropathic syndromes in giant cell (temporal) arteritis. Neurology. 1988 May;38(5):685-9. 摘要

4. Grant SW, Underhill HC, Atkin P. Giant cell arteritis affecting the tongue: a case report and review of the literature. Dent Update. 2013 Oct;40(8):669-70, 673-4, 677. 摘要

5. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008 Jul 19;372(9634):234-45. 摘要

6. Bongartz T, Matteson EL. Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol. 2006 Jan;18(1):10-7. 摘要

7. Kermani TA, Matteson EL, Hunder GG, et al. Symptomatic lower extremity vasculitis in giant cell arteritis: a case series. J Rheumatol. 2009 Oct;36(10):2277-83. 摘要

8. Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002 Jul 25;347(4):261-71. 摘要

9. Salvarani C, Gabriel SE, O'Fallon WM, et al. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med. 1995 Aug 1;123(3):192-4. 摘要

10. Kermani TA, Schäfer VS, Crowson CS, et al. Increase in age at onset of giant cell arteritis: a population-based study. Ann Rheum Dis. 2010 Apr;69(4):780-1. 摘要

11. Gonzalez-Gay MA, Garcia-Porrua C, Rivas MJ, et al. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. Ann Rheum Dis. 2001 Apr;60(4):367-71.全文  摘要

12. Pucelj NP, Hočevar A, Ješe R, et al. The incidence of giant cell arteritis in Slovenia. Clin Rheumatol. 2019 Feb;38(2):285-290.全文  摘要

13. Salvarani C, Macchioni P, Zizzi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum. 1991 Mar;34(3):351-6. 摘要

14. Weyand CM, Hicok KC, Hunder GG, et al. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest. 1992 Dec;90(6):2355-61.全文  摘要

15. Weyand CM, Ma-Krupa W, Pryshchep O, et al. Vascular dendritic cells in giant cell arteritis. Ann N Y Acad Sci. 2005 Dec;1062:195-208. 摘要

16. Weyand CM, Schonberger J, Oppitz U, et al. Distinct vascular lesions in giant cell arteritis share identical T-cell clonotypes. J Exp Med. 1994 Mar 1;179(3):951-60.全文  摘要

17. Weyand CM, Ma-Krupa W, Goronzy JJ. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev. 2004 Jan;3(1):46-53. 摘要

18. Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994 Oct 1;121(7):484-91. 摘要

19. Salvarani C, Crowson CS, O'Fallon WM, et al. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum. 2004 Apr 15;51(2):264-8. 摘要

20. Nordborg E, Bengtsson BA. Epidemiology of biopsy-proven giant cell arteritis (GCA). J Intern Med. 1990 Apr;227(4):233-6. 摘要

21. Baldursson O, Steinsson K, Bjornsson J, et al. Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis. Arthritis Rheum. 1994 Jul;37(7):1007-12. 摘要

22. Larsson K, Mellstrom D, Nordborg E, et al. Early menopause, low body mass index, and smoking are independent risk factors for developing giant cell arteritis. Ann Rheum Dis. 2006 Apr;65(4):529-32. 摘要

23. Nordborg E, Nordborg C. Giant cell arteritis: epidemiological clues to its pathogenesis and an update on its treatment. Rheumatology (Oxford). 2003 Mar;42(3):413-21.全文  摘要

24. Duhaut P, Pinede L, Demolombe-Rague S, et al. Giant cell arteritis and cardiovascular risk factors: a multicenter, prospective case-control study. Groupe de Recherche sur l'Arterite a Cellules Geantes. Arthritis Rheum. 1998 Nov;41(11):1960-5. 摘要

25. Brennan DN, Ungprasert P, Warrington KJ, et al. Smoking as a risk factor for giant cell arteritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2018 Dec;48(3):529-37. 摘要

26. Petursdottir V, Johansson H, Nordborg E, et al. The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology (Oxford). 1999 Dec;38(12):1208-12.全文  摘要

27. England BR, Mikuls TR, Xie F, et al. Herpes zoster as a risk factor for incident giant cell arteritis. Arthritis Rheumatol. 2017 Dec;69(12):2351-8. 摘要

28. Muratore F, Croci S, Tamagnini I, et al. No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis. Semin Arthritis Rheum. 2017 Oct;47(2):235-40. 摘要

29. Nagel MA, White T, Khmeleva N, et al. Analysis of varicella-zoster virus in temporal arteries biopsy positive and negative for giant cell arteritis. JAMA Neurol. 2015 Nov;72(11):1281-7.全文  摘要

30. Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA. 2002 Jan 2;287(1):92-101. 摘要

31. Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021 Aug;73(8):1349-65.全文  摘要

32. Achkar AA, Lie JT, Hunder GG, et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994 Jun 15;120(12):987-92. 摘要

33. Ray-Chaudhuri N, Kine DA, Tijani SO, et al. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol. 2002 May;86(5):530-2. 摘要

34. Maleszewski JJ, Younge BR, Fritzlen JT, et al. Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod Pathol. 2017 Jun;30(6):788-96.全文  摘要

35. Muratore F, Kermani TA, Crowson CS, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford). 2015 Mar;54(3):463-70.全文  摘要

36. Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018 May;77(5):636-43.全文  摘要

37. Ball EL, Walsh SR, Tang TY, et al. Role of ultrasonography in the diagnosis of temporal arteritis. Br J Surgery. 2010 Dec;97(12):1765-71. 摘要

38. Karassa FB, Matsagas MI, Schmidt WA, et al. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med. 2005 Mar 1;142(5):359-69. 摘要

39. Rinagel M, Chatelus E, Jousse-Joulin S, et al. Diagnostic performance of temporal artery ultrasound for the diagnosis of giant cell arteritis: a systematic review and meta-analysis of the literature. Autoimmun Rev. 2019 Jan;18(1):56-61. 摘要

40. Kermani TA, Warrington KJ. Recent advances in diagnostic strategies for giant cell arteritis. Curr Neurol Neurosci Rep. 2012 Apr;12(2):138-44. 摘要

41. Besson FL, Parienti JJ, Bienvenu B, et al. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1764-72. 摘要

42. Soussan M, Nicolas P, Schramm C, et al. Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. Medicine (Baltimore). 2015 Apr;94(14):e622.全文  摘要

43. Simundic AM, Bölenius K, Cadamuro J, et al. Joint EFLM-COLABIOCLI recommendation for venous blood sampling. Clin Chem Lab Med 2018;56(12):2015-38. 摘要

44. Epperly TD, Moore KE, Harrover JD. Polymyalgia rheumatica and temporal arthritis. Am Fam Physician. 2000 Aug 15;62(4):789-96, 801.全文  摘要

45. Seo P, Stone JH. Large-vessel vasculitis. Arthritis Rheum. 2004 Feb 15;51(1):128-39.全文  摘要

46. Gertz MA, Kyle RA, Griffing WL, et al. Jaw claudication in primary systemic amyloidosis. Medicine (Baltimore). 1986 May;65(3):173-9. 摘要

47. Fraser JA, Weyand CM, Newman NJ, et al. The treatment of giant cell arteritis. Rev Neurol Dis. 2008 Summer;5(3):140-52. 摘要

48. Younge BR, Cook BE Jr, Bartley GB, et al. Initiation of glucocorticoid therapy: before or after temporal artery biopsy? Mayo Clin Proc. 2004 Apr;79(4):483-91. 摘要

49. Singh AG, Kermani TA, Crowson CS, et al. Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J Rheumatol. 2015 Feb;42(2):309-15.全文  摘要

50. Chan CC, Paine M, O'Day J. Steroid management in giant cell arteritis. Br J Ophthalmol. 2001 Sep;85(9):1061-4. 摘要

51. Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017 Jul 27;377(4):317-28. 摘要

52. American College of Rheumatology. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis - guideline summary. Nov 2022 [internet publication].全文

53. Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016 Jun;75(6):952-7.全文  摘要

54. Wilson JC, Sarsour K, Collinson N, et al. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis. Semin Arthritis Rheum. 2017 Jun;46(6):819-27.全文  摘要

55. Yu E, Chang JR. Giant cell arteritis: updates and controversies. Front. Ophthalmol. 2022 Mar 17(2):848861.全文

56. Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford). 2012 Jan;51(1):151-6. 摘要

57. Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016 May 7;387(10031):1921-7. 摘要

58. Monti S, Águeda AF, Luqmani RA, et al. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open. 2019 Sep 16;5(2):e001003.全文  摘要

59. Berti A, Cornec D, Medina Inojosa JR, et al. Treatments for giant cell arteritis: Meta-analysis and assessment of estimates reliability using the fragility index. Semin Arthritis Rheum. 2018 Aug;48(1):77-82. 摘要

60. Medicines and Healthcare products Regulatory Agency. Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation. Jul 2019 [internet publication].全文

61. Unizony S, McCulley TJ, Spiera R, et al. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations. Arthritis Res Ther. 2021 Jan 6;23(1):8.全文  摘要

62. Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011 Mar;50(3):552-62.全文  摘要

63. Xie F, Yun H, Bernatsky S, et al. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016 Nov;68(11):2612-7.全文  摘要

64. Strangfeld A, Richter A, Siegmund B, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis. 2017 Mar;76(3):504-10.全文  摘要

65. Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002 May;46(5):1309-18. 摘要

66. Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001 Jan 16;134(2):106-14. 摘要

67. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007 Aug;56(8):2789-97. 摘要

68. Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017 Apr;69(4):837-45.全文  摘要

69. Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004 Apr;50(4):1332-7. 摘要

70. Lee MS, Smith SD, Galor A, et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006 Oct;54(10):3306-9. 摘要

71. Narváez J, Bernad B, Gómez-Vaquero C, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol. 2008 May-Jun;26(3 suppl 49):S57-62. 摘要

72. Salvarani C, Della Bella C, Cimino L, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford). 2009 Mar;48(3):250-3.全文  摘要

73. Martínez-Taboada VM, López-Hoyos M, Narvaez J, et al. Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis. Autoimmun Rev. 2014 Aug;13(8):788-94. 摘要

74. Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020 Jan;79(1):19-30.全文  摘要

75. Mollan SP, Sharrack N, Burdon MA, et al. Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database Syst Rev. 2014 Aug 3;(8):CD010453.全文  摘要

76. Loock J, Henes J, Kötter I, et al. Treatment of refractory giant cell arteritis with cyclophosphamide:a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S70-6. 摘要

77. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995 Apr 1;122(7):502-7. 摘要

78. Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003 Dec;48(12):3532-7. 摘要

79. Tomasson G, Peloquin C, Mohammad A, et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med. 2014 Jan 21;160(2):73-80.全文  摘要

80. Amiri N, De Vera M, Choi HK, et al. Increased risk of cardiovascular disease in giant cell arteritis: a general population-based study. Rheumatology (Oxford). 2016 Jan;55(1):33-40. 摘要

81. Aiello PD, Trautmann JC, McPhee TJ, et al. Visual prognosis in giant cell arteritis. Ophthalmology. 1993 Apr;100(4):550-5. 摘要

82. Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med. 2001 Aug 15;111(3):211-7. 摘要

83. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996 Jan;71(1):5-13. 摘要

84. Kermani TA, Ytterberg SR, Warrington KJ. Pneumocystis jiroveci pneumonia in giant cell arteritis: a case series. Arthritis Care Res (Hoboken). 2011 May;63(5):761-5. 摘要

85. Mackie SL, Hensor EM, Morgan AW, et al. Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. Ann Rheum Dis. 2014 Jan;73(1):143-8. 摘要

86. Bienvenu B, Ly KH, Lambert M, et al. Management of giant cell arteritis: recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne. 2016 Mar;37(3):154-65. 摘要